SG11201707429VA - Novel therapies for cancer - Google Patents

Novel therapies for cancer

Info

Publication number
SG11201707429VA
SG11201707429VA SG11201707429VA SG11201707429VA SG11201707429VA SG 11201707429V A SG11201707429V A SG 11201707429VA SG 11201707429V A SG11201707429V A SG 11201707429VA SG 11201707429V A SG11201707429V A SG 11201707429VA SG 11201707429V A SG11201707429V A SG 11201707429VA
Authority
SG
Singapore
Prior art keywords
cancer
novel therapies
therapies
novel
Prior art date
Application number
SG11201707429VA
Inventor
Peter Richardson
Jacqueline Mary Walling
Claudio Festuccia
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of SG11201707429VA publication Critical patent/SG11201707429VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201707429VA 2015-04-02 2016-04-01 Novel therapies for cancer SG11201707429VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562141980P 2015-04-02 2015-04-02
PCT/IB2016/051880 WO2016157149A1 (en) 2015-04-02 2016-04-01 Novel therapies for cancer

Publications (1)

Publication Number Publication Date
SG11201707429VA true SG11201707429VA (en) 2017-10-30

Family

ID=55702039

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201909188X SG10201909188XA (en) 2015-04-02 2016-04-01 Novel therapies for cancer
SG11201707429VA SG11201707429VA (en) 2015-04-02 2016-04-01 Novel therapies for cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201909188X SG10201909188XA (en) 2015-04-02 2016-04-01 Novel therapies for cancer

Country Status (19)

Country Link
US (1) US11311552B2 (en)
EP (1) EP3277284B1 (en)
JP (1) JP6927882B2 (en)
KR (1) KR20170132314A (en)
CN (2) CN107438437B (en)
AU (1) AU2016242118B2 (en)
BR (1) BR112017019437A2 (en)
CA (1) CA2979167A1 (en)
DK (1) DK3277284T3 (en)
EA (1) EA037555B1 (en)
ES (1) ES2826558T3 (en)
HK (1) HK1245120A1 (en)
HU (1) HUE051341T2 (en)
IL (1) IL254149A0 (en)
MX (1) MX2017011981A (en)
PL (1) PL3277284T3 (en)
PT (1) PT3277284T (en)
SG (2) SG10201909188XA (en)
WO (1) WO2016157149A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
MX2017011981A (en) 2015-04-02 2018-01-10 Proximagen Ltd Novel therapies for cancer.
GB201604213D0 (en) 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
GB201703907D0 (en) * 2017-03-10 2017-04-26 Proximagen Ltd Novel therapies for cancer
WO2020222189A1 (en) 2019-05-02 2020-11-05 Proximagen, Llc Crystalline form of 6-[4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide
WO2020222190A1 (en) 2019-05-02 2020-11-05 Proximagen, Llc Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide
WO2021261601A1 (en) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 Method for selecting cancer patient for which combination therapy of retinoid and cancer treatment agent will be effective, and combined drug of retinoid and cancer treatment agent

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
FR2769913B1 (en) 1997-10-16 2000-03-10 Pf Medicament NEW CYCLOHEXANIC DERIVATIVES DIFUNCTIONALIZED IN 1, 4, THEIR PREPARATION AND THEIR HUMAN THERAPEUTIC APPLICATION
SE9902987D0 (en) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
CA2414461A1 (en) 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
AR036366A1 (en) 2001-08-29 2004-09-01 Schering Corp USEFUL PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS, THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A KIT
WO2003082855A1 (en) 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
WO2004087068A2 (en) * 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
FR2854633B1 (en) 2003-05-07 2005-06-24 Sanofi Synthelabo PIPERIDINYL-AND PIPERAZINYL-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP1708703A4 (en) 2003-12-11 2008-04-09 Anormed Inc Chemokine receptor binding compounds
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CA2598460C (en) 2005-02-16 2013-05-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
JP2008530218A (en) 2005-02-16 2008-08-07 シェーリング コーポレイション Piperazine-piperidine substituted with pyridyl and phenyl having CXCR3 antagonist activity
MX2007009947A (en) 2005-02-16 2007-09-26 Schering Corp Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity.
JP2008530212A (en) 2005-02-16 2008-08-07 シェーリング コーポレイション Piperazine-piperidine having CXCR3 antagonist activity
US7417045B2 (en) 2005-02-16 2008-08-26 Schering Corporation Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2006130426A2 (en) 2005-05-27 2006-12-07 Kemia, Inc. Modulators of ccr-5 activity
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
MX2008012161A (en) 2006-03-21 2008-10-03 Schering Corp Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity.
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
KR20090043512A (en) 2006-07-14 2009-05-06 쉐링 코포레이션 Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity
US8414983B2 (en) 2006-09-02 2013-04-09 MERCK Patent Gesellschaft mit beschränkter Haftung Particle beam process for the alignment of reactive mesogens
KR20090068263A (en) 2006-09-21 2009-06-25 액티브스 바이오사이언시즈, 인크. Serine hydrolase inhibitors
MX2009005252A (en) 2006-11-17 2009-05-28 Abbott Lab Aminopyrrolidines as chemokine receptor antagonists.
EP2094688A1 (en) 2006-12-22 2009-09-02 Schering Corporation Heterocyclic compounds with cxcr3 antagonist activity
EP2778155A1 (en) 2007-01-31 2014-09-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
WO2008121065A1 (en) 2007-03-30 2008-10-09 Astrazeneca Ab Novel pyrrolidine derivatives as antagonists of the chemokine receptor
EP2231636B1 (en) 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
US20110091486A1 (en) * 2008-02-29 2011-04-21 John Martin Brown Inhibition of post-radiation tumor growth
US8288373B2 (en) 2008-11-04 2012-10-16 Chemocentryx, Inc. Modulators of CXCR7
JP2012533553A (en) 2009-07-15 2012-12-27 アボット・ラボラトリーズ Pyrrolopyridine kinase inhibitor
KR20110123657A (en) 2010-05-07 2011-11-15 에스케이케미칼주식회사 Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same
WO2012047339A2 (en) * 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
GB201017048D0 (en) * 2010-10-08 2010-11-24 Ucl Business Plc Composition
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
EP2935215B1 (en) * 2012-12-20 2019-11-13 Lu, Qing-Bin Radiosensitizer compounds for use in combination with radiation
MX2017011981A (en) 2015-04-02 2018-01-10 Proximagen Ltd Novel therapies for cancer.
GB201604213D0 (en) 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
GB201703907D0 (en) 2017-03-10 2017-04-26 Proximagen Ltd Novel therapies for cancer

Also Published As

Publication number Publication date
US11311552B2 (en) 2022-04-26
HUE051341T2 (en) 2021-03-01
PT3277284T (en) 2020-11-11
IL254149A0 (en) 2017-10-31
KR20170132314A (en) 2017-12-01
SG10201909188XA (en) 2019-11-28
EA037555B1 (en) 2021-04-13
CN112569242A (en) 2021-03-30
AU2016242118B2 (en) 2021-07-08
BR112017019437A2 (en) 2018-05-02
EP3277284A1 (en) 2018-02-07
CN107438437A (en) 2017-12-05
WO2016157149A9 (en) 2016-12-08
JP6927882B2 (en) 2021-09-01
EP3277284B1 (en) 2020-08-05
ES2826558T3 (en) 2021-05-18
PL3277284T3 (en) 2021-03-08
CA2979167A1 (en) 2016-10-06
US20180078563A1 (en) 2018-03-22
CN107438437B (en) 2021-01-01
JP2018510154A (en) 2018-04-12
HK1245120A1 (en) 2018-08-24
MX2017011981A (en) 2018-01-10
DK3277284T3 (en) 2020-10-26
AU2016242118A1 (en) 2017-10-05
WO2016157149A1 (en) 2016-10-06
EA201791953A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
ZA201702382B (en) Combination therapy for cancer
IL254705B (en) Combination therapy for cancer
IL253573A0 (en) Combination therapies for treating cancers
HK1259342A1 (en) Combination therapies for treating cancer
HK1231381A1 (en) Combination therapy for cancer
HK1245120A1 (en) Novel therapies for cancer
HK1243598A1 (en) Combination therapies
IL246761A0 (en) Combination therapy for cancer
HK1255939A1 (en) Combination therapies for treating cancers
GB201519734D0 (en) Cancer therapy
GB201703907D0 (en) Novel therapies for cancer
GB201508480D0 (en) Cancer
HK1254687A1 (en) Combination therapy for cancer
HRP20210383T8 (en) Combination therapy for cancer
GB201511609D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy
GB201417819D0 (en) Agents for cancer therapy
GB201411884D0 (en) Cancer therapy
GB201409457D0 (en) Molecules for cancer therapy
GB201406529D0 (en) Molecules for cancer therapy